The proof-of-concept demonstrates the power of pairing AI with lab orchestration solutions to automate molecular screening ...

Collaborative project with world leader in AI computing demonstrates Artificial workflows and model integration for self-driving generative virtual screening in drug discovery. Company also announces ...

Nvidia Corporation is poised for >70% YoY growth in Q4 FY25, driven by AI dominance and a $300B healthcare opportunity. Explore more details here.

“Our partnership is going to focus on developing true foundation models for biology using Nvidia BioNeMo and DGX Cloud. All of our resulting work is going to be shared and contributed back to ...

Innophore will launch the CavitOmiX AI tool to screen for new drugs, predict side effects, and repurpose existing molecules.

Working with Illumina, hopes to improve genomics research by means of enhanced accessibility via NVIDIA Clara and BioNeMo systems and AI-powered analytics. To speed molecular generating and ...

SAN FRANCISCO—Nvidia will partner with Illumina to apply genomics and AI technologies to analyze and interpret multi-omic data in drug discovery, clinical research, and human health, the ...

Collaboration combines Illumina's sequencing technologies and Illumina Connected Software with NVIDIA tools to develop biological foundation models SAN DIEGO, Jan. 13, 2025 /PRNewswire ...

Artificial, Inc (“Artificial”), announced proof-of-concept data demonstrating the Artificial Platform’s workflow and model integration capabilities using NVIDIA BioNeMo, a generative AI platform for ...